Non-alcoholic Fatty Liver Disease Clinical Trial
Official title:
Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease (BEN) Study
The purpose of this is to analyse human exhaled breath by means of a device called electronic nose(eNose) in patients with non-alcoholic fatty liver disease (NAFLD) as a way to non-invasive assessment of liver disease.This device is medically adapted and clinically validated in patients with lung conditions.
Human exhaled breath contains over 3000 volatile organic compounds (VOCs) that vary in
relative concentration in health and disease. Metabolic disorders affecting the liver, such
as NAFLD, produce disproportionate organic compounds produced as a by-product of metabolism
and thus expired in exhaled breath, excreted in urine and detectable in blood. NAFLD
prevalence is increasing and has reached epidemic proportions affecting 90% of obese adults
and 22%-53% of obese children.Liver biopsy is the gold standard in diagnosing NAFLD, but it
is unpleasant and can lead to complications. There is an unmet need to develop a non-invasive
method of assessing liver disease. Comon Invent (Delft, Netherlands) together with the
respiratory department at the Amsterdam Medical Centre (AMC), University of Amsterdam, have
adapted the electronic nose known as SpiroNose as a prototype device for clinical use.
Sensitive electronic sensors detect molecules in breath and generate signals. Complex
algorithms and analytical technics allow pattern recognition of breath samples from different
subjects. Well charaterised patients will be selected into clinical categories of
non-alcoholic fatty liver disease with and without cirrhosis and be compared with healthy
individuals.
Edinburgh will be the only site conducting this study. In addition to exhaled breath
analysis, blood and urine will be collected to study the end products of
metabolism.Furthermore, stool and urine collected from some subjects will be analysed to
understand the role of gut bacteria in fermentation, metabolic products as a result cause VOC
production.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |